Increased serum amyloid A and its association with autoantibodies, acute phase reactants and disease activity in patients with rheumatoid arthritis

Shen,Chen; Sun,Xu‑Guo; Liu,Na; Mu,Yun; Hong,Cheng‑Cheng; Wei,Wei; Zheng,Fang

doi:10.3892/mmr.2014.2804

Increased serum amyloid A and its association with autoantibodies, acute phase reactants and disease activity in patients with rheumatoid arthritis

Authors:
- Chen Shen
- Xu‑Guo Sun
- Na Liu
- Yun Mu
- Cheng‑Cheng Hong
- Wei Wei
- Fang Zheng
View Affiliations

Affiliations: Department of Clinical Immunology, School of Laboratory Medicine, Tianjin Medical University, Tianjin 300203, P.R. China, Department of Medical Laboratory, Tianjin Hospital of Children, Tianjin 300074, P.R. China, Department of Rheumatology, General Hospital, Tianjin Medical University, Tianjin 300052, P.R. China
Published online on: October 29, 2014 https://doi.org/10.3892/mmr.2014.2804
Pages: 1528-1534

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Determination of disease activity in patients with rheumatoid arthritis (RA) has become an important component for RA management. The aim of the present study was to investigate the association between circulating levels of serum amyloid A (SAA) and disease activity in RA patients. The types of disease and the respective number of patients enrolled in the present study were as follows: RA, 88; osteoarthritis (OA), 54; systemic lupus erythematosus (SLE), 43; and other autoimmune diseases, 30, as well as 50 healthy controls (HC). SAA levels were measured using an ELISA assay and western blot analysis was used to detect serum SAA levels. The correlations between SAA levels and disease activity score for 28 joints (DAS28), erythrocyte sedimentation rate (ESR) and C‑reactive protein (CRP), respectively, were evaluated; in addition, the presence and absence of rheumatoid factor (RF) and anti‑cyclic citrullinated peptide antibody (anti‑CCP) were detected in respect to SAA levels. The results of the present study demonstrated that serum levels of SAA in RA patients were significantly increased compared to those of the OA, SLE, others and HC patients (P<0.05). SAA levels were found to be positively correlated with DAS28, ESR and CRP levels (R2=0.6174, 0.4422 and 0.3919, respectively). In addition, anti‑CCP was not correlated with DAS28 (R2=0.0154). Furthermore, increased SAA levels were detected in patients with positive anti‑CCP compared with those in anti‑CCP negative subjects (P<0.01). In conclusion, the results of the present study provided further evidence for possible roles of SAA in RA, which indicated that it may be a useful biomarker for assessing disease severity and may provide additional information about disease activity.

View Figures

View References

1	Scott DL, Wolfe F and Huizinga TW: Rheumatoid arthritis. Lancet. 376:1094–1108. 2010. View Article : Google Scholar : PubMed/NCBI
2	McInnes IB and Schett G: The pathogenesis of rheumatoid arthritis. N Engl J Med. 365:2205–2219. 2011. View Article : Google Scholar : PubMed/NCBI
3	Emery P: Evidence supporting the benefit of early intervention in rheumatoid arthritis. J Rheumatol. 66:3–8. 2002.
4	Fransen J and van Riel PL: The disease activity score and the EULAR response criteria. Clin Exp Rheumatol. 23(5 Suppl 39): S93–S99. 2005.PubMed/NCBI
5	Aletaha D, Landewe R, Karonitsch T, et al: EULAR, ACR: Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Arthritis Rheum. 59:1371–1377. 2008. View Article : Google Scholar : PubMed/NCBI
6	Matsui T, Kuga Y, Kaneko A, et al: Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan. Ann Rheum Dis. 66:1221–1226. 2007. View Article : Google Scholar : PubMed/NCBI
7	Da Mota LM, dos Santos Neto LL, Burlingame R, et al: Laboratory characteristics of a cohort of patients with early rheumatoid arthritis. Rev Bras Rheumatol. 50:375–388. 2010.
8	Aletaha D, Neogi T, Silman AJ, et al: 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 62:2569–2581. 2010. View Article : Google Scholar : PubMed/NCBI
9	Papadopoulos NG, Tsiaousis GZ, Pavlitou-Tsiontsi A, Giannakou A and Galanopoulou VK: Does the presence of anti-CCP autoantibodies and their serum levels influence the severity and activity in rheumatoid arthritis patients? Clin Rev Allergy Immunol. 34:11–15. 2008. View Article : Google Scholar : PubMed/NCBI
10	Mullan RH, Bresnihan B, Golden-Mason L, et al: Acute-phase serum amyloid A stimulation of angiogenesis, leukocyte recruitment, and matrix degradation in rheumatoid arthritis through an NF-κB-dependent signal transduction pathway. Arthritis Rheum. 54:105–114. 2006. View Article : Google Scholar
11	Dong Z, Wu T, Qin W, et al: Serum amyloid A directly accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Mol Med. 17:1357–1364. 2011. View Article : Google Scholar : PubMed/NCBI
12	Eklund KK, Niemi K and Kovanen PT: Immune functions of serum amyloid A. Crit Rev Immunol. 32:335–348. 2012. View Article : Google Scholar : PubMed/NCBI
13	Jung SY, Park MC, Park YB and Lee SK: Serum amyloid a as a useful indicator of disease activity in patients with ankylosing spondylitis. Yonsei Med J. 48:218–224. 2007. View Article : Google Scholar : PubMed/NCBI
14	Cantarini L, Giani T, Fioravanti A, et al: Serum amyloid A circulating levels and disease activity in patients with juvenile idiopathic arthritis. Yonsei Med J. 53:1045–1048. 2012. View Article : Google Scholar : PubMed/NCBI
15	Shimojima Y, Matsuda M, Gono T, Ishii W and Ikeda S: Serum amyloid A as a potent therapeutic marker in a refractory patient with polymyalgia rheumatica. Intern Med. 44:1009–1012. 2005. View Article : Google Scholar : PubMed/NCBI
16	Ferrari R, Tanni SE, Caram LM, Corrêa C, Corrêa CR, et al: Three-year follow-up of interleukin 6 and C-reactive protein in chronic obstructive pulmonary disease. Respir Res. 20:14–24. 2013.
17	O’Hara R, Murphy EP, Whitehead AS, FitzGerald O and Bresnihan B: Acute-phase serum amyloid A production by rheumatoid arthritis synovial tissue. Arthritis Res. 2:142–144. 2000. View Article : Google Scholar
18	Momohara S, Okamoto H and Yamanaka H: Chondrocyte of rheumatoid arthritis serve as a source of intra-articular acute-phase serum amyloid A protein. Clin Chim Acta. 398:155–156. 2008. View Article : Google Scholar : PubMed/NCBI
19	Vallon R, Freuler F, Desta-Tsedu N, et al: Serum amyloid A (apoSAA) expression is up-regulated in rheumatoid arthritis and induces transcription of matrix metalloproteinases. J Immunol. 66:2801–2807. 2001. View Article : Google Scholar
20	de Seny D, Cobraiville G, Charlier E, et al: Acute-phase serum amyloid a in osteoarthritis: regulatory mechanism and proinflammatory properties. PloS One. 8:e667692013. View Article : Google Scholar : PubMed/NCBI
21	Metawi SA, Abbas D, Kamal MM and Ibrahim MK: Serum and synovial fluid levels of interleukin-17 in correlation with disease activity in patients with RA. Clin Rheumatol. 30:1201–1207. 2011. View Article : Google Scholar : PubMed/NCBI
22	Migita K, Koga T, Torigoshi T, et al: Serum amyloid A protein stimulates CCL20 production in rheumatoid synoviocytes. Rheumatology (Oxford). 48:741–747. 2009. View Article : Google Scholar
23	Mullan RH, Bresnihan B, Golden-Mason L, et al: Acute-phase serum amyloid A stimulation of angiogenesis, leukocyte recruitment, and matrix degradation in rheumatoid arthritis through an NF-κB-dependent signal transduction pathway. Arthritis Rheum. 54:105–114. 2006. View Article : Google Scholar
24	Okamoto H, Katagiri Y, Kiire A, Momohara S and Kamatani N: Serum amyloid A activates nuclear factor-kappa B in rheumatoid synovial fibroblasts through binding to receptor of advanced glycation end-products. J Rheumatol. 35:752–756. 2008.PubMed/NCBI
25	Farheen K and Agarwal SK: Assessment of disease activity and treatment outcomes in rheumatoid arthritis. J Manag Care Pharm. 17(9 Suppl B): S09–S13. 2011.PubMed/NCBI
26	Connolly M, Mullan RH, McCormick J, et al: Acute-phase serum amyloid A regulates tumor necrosis factor α and matrix turnover and predicts disease progression in patients with inflammatory arthritis before and after biologic therapy. Arthritis Rheum. 64:1035–1045. 2012. View Article : Google Scholar
27	Thorn CF, Lu ZY and Whitehead AS: Regulation of the human acute phase serum amyloid A genes by tumour necrosis factor-alpha, interleukin-6 and glucocorticoids in hepatic and epithelial cell lines. Scand J Immunol. 59:152–158. 2004. View Article : Google Scholar : PubMed/NCBI
28	Agrawal S, Misra R and Aggarwal A: Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA. Clin Rheumatol. 26:201–204. 2007. View Article : Google Scholar